Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringinglife-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.

Biotechnology

Pharmaceutical

Therapeutics

Syncromune™

This department focuses on the innovation and development of new products and technologies.

Research and Development

This department manages the organization's financial planning, reporting, and control activities.

Finance Department

This department oversees clinical operations and the development of drug substances and products.

Clinical Development

This department oversees the planning and execution of clinical trials to ensure compliance with regulatory standards and operational efficiency.

Clinical Operations

This department focuses on high-level strategic direction and decision-making within the organization.

Executive Leadership

This department manages employee relations, recruitment, and organizational culture to support the workforce.

Human Resources

This department focuses on advancing research and strategies in immunology and the development of medical devices.

People (0)

Jobs (0)

Other teams

Finance Department

Clinical Development

Clinical Operations

Executive Leadership

Human Resources

Immunology and Device Development